Jakafi failed the primary endpoint in a Covid-19 study. But Incyte is still going to FDA with a compassionate use pitch

Jakafi disappointed Incyte once when it failed to prevent severe complications of Covid-19. The JAK inhibitor has fallen short again in another Phase III study, failing to keep a more critical subgroup of patients from dying.